These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8134167)
1. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. An in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency. Tein I; DiMauro S; Xie ZW; De Vivo DC Pediatr Res; 1993 Sep; 34(3):281-7. PubMed ID: 8134167 [TBL] [Abstract][Full Text] [Related]
2. Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Tein I; DiMauro S; Xie ZW; De Vivo DC J Inherit Metab Dis; 1995; 18(3):313-22. PubMed ID: 7474898 [TBL] [Abstract][Full Text] [Related]
3. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Tein I; Xie ZW Biochem Biophys Res Commun; 1994 Oct; 204(2):753-8. PubMed ID: 7980539 [TBL] [Abstract][Full Text] [Related]
4. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Tein I; De Vivo DC; Bierman F; Pulver P; De Meirleir LJ; Cvitanovic-Sojat L; Pagon RA; Bertini E; Dionisi-Vici C; Servidei S Pediatr Res; 1990 Sep; 28(3):247-55. PubMed ID: 2235122 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts. Tein I; Bukovac SW; Xie ZW Arch Biochem Biophys; 1996 May; 329(2):145-55. PubMed ID: 8638946 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients]. Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630 [TBL] [Abstract][Full Text] [Related]
7. Carnitine metabolism in valproate-treated rats: the effect of L-carnitine supplementation. Nishida N; Sugimoto T; Araki A; Woo M; Sakane Y; Kobayashi Y Pediatr Res; 1987 Nov; 22(5):500-3. PubMed ID: 3120144 [TBL] [Abstract][Full Text] [Related]
8. Relationship of carnitine and carnitine precursors lysine, epsilon-N-trimethyllysine, and gamma-butyrobetaine in drug-induced carnitine depletion. Melegh B; Pap M; Bock I; Rebouche CJ Pediatr Res; 1993 Oct; 34(4):460-4. PubMed ID: 8255678 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Nakajima Y; Ito T; Maeda Y; Ichiki S; Kobayashi S; Ando N; Hussein MH; Kurono Y; Sugiyama N; Togari H Brain Dev; 2011 Nov; 33(10):816-23. PubMed ID: 21196091 [TBL] [Abstract][Full Text] [Related]
10. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. Knapp AC; Todesco L; Beier K; Terracciano L; Sägesser H; Reichen J; Krähenbühl S J Pharmacol Exp Ther; 2008 Feb; 324(2):568-75. PubMed ID: 17986647 [TBL] [Abstract][Full Text] [Related]
11. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis. Voisard R; Krebs R; Baur R; Hombach V Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518 [TBL] [Abstract][Full Text] [Related]
12. Valproate induces in vitro accumulation of long-chain fatty acylcarnitines. Silva MF; Jakobs C; Duran M; de Almeida IT; Wanders RJ Mol Genet Metab; 2001 Aug; 73(4):358-61. PubMed ID: 11509020 [TBL] [Abstract][Full Text] [Related]
13. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Gibbs JP; Adeyeye MC; Yang Z; Shen DD Epilepsy Res; 2004 Jan; 58(1):53-66. PubMed ID: 15066675 [TBL] [Abstract][Full Text] [Related]
14. L-carnitine replacement therapy in chronic valproate treatment. Melegh B; Kerner J; Acsádi G; Lakatos J; Sándor A Neuropediatrics; 1990 Feb; 21(1):40-3. PubMed ID: 2107456 [TBL] [Abstract][Full Text] [Related]
15. Carnitine deficiency during valproic acid treatment. Van Wouwe JP Int J Vitam Nutr Res; 1995; 65(3):211-4. PubMed ID: 8830002 [TBL] [Abstract][Full Text] [Related]
16. Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Michaelis M; Köhler N; Reinisch A; Eikel D; Gravemann U; Doerr HW; Nau H; Cinatl J Biochem Pharmacol; 2004 Aug; 68(3):531-8. PubMed ID: 15242819 [TBL] [Abstract][Full Text] [Related]
17. Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. Morand R; Todesco L; Donzelli M; Fischer-Barnicol D; Mullen PJ; Krähenbühl S Ther Drug Monit; 2012 Aug; 34(4):406-14. PubMed ID: 22743351 [TBL] [Abstract][Full Text] [Related]
18. Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells. Kurita M; Nishino S; Ohtomo K; Rai M; Shirakawa H; Mashiko H; Niwa S; Nakahata N Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):600-4. PubMed ID: 17258372 [TBL] [Abstract][Full Text] [Related]
19. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Triggs WJ; Gilmore RL; Millington DS; Cibula J; Bunch TS; Harman E Int J Clin Pharmacol Ther; 1997 Sep; 35(9):353-6. PubMed ID: 9314085 [TBL] [Abstract][Full Text] [Related]
20. Effect of L-carnitine supplementation on acute valproate intoxication. Murakami K; Sugimoto T; Woo M; Nishida N; Muro H Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]